On December 20, 2024, the FDA granted accelerated approval to the combination of encorafenib (Braftovi), cetuximab (Erbitux), ...

Sacituzumab govitecan, currently indicated in triple-negative breast cancer (TNBC), is undergoing evaluation in NSCLC. In ...

The antibody-drug conjugate showed a higher objective response rate but failed to meet the primary OS endpoint in patients ...

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Esophageal Cancer.

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Hepatocellular Carcinoma.

Daiichi Sankyo has claimed approval in Japan, its home market, for TROP2-targeting antibody-drug conjugate (ADC) datopotamab ...

The FDA has granted breakthrough therapy designation Trodelvy for adults with extensive-stage small cell lung cancer who ...

Sacituzumab govitecan failed to improve overall survival in the EVOKE-01 trial, but was well tolerated with no new safety signals. Comprehensive genomic profiling is crucial to address testing ...

Gilead Sciences GILD announced that its first-in-class Trop-2-directed antibody-drug conjugate, Trodelvy (sacituzumab ...

A Phase 2 study showed encouraging results with Trodelvy as a second-line treatment for extensive-stage small cell lung ...

Gilead Sciences GILD announced that its first-in-class Trop-2-directed antibody-drug conjugate, Trodelvy (sacituzumab govitecan-hziy), has been granted a second Breakthrough Therapy designation by ...